203 related articles for article (PubMed ID: 23327575)
21. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
22. Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism.
Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):751-767. PubMed ID: 29876844
[TBL] [Abstract][Full Text] [Related]
23. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
24. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
25. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
Lown KS; Kolars JC; Thummel KE; Barnett JL; Kunze KL; Wrighton SA; Watkins PB
Drug Metab Dispos; 1994; 22(6):947-55. PubMed ID: 7895614
[TBL] [Abstract][Full Text] [Related]
26. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
27. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.
Vanhove T; Annaert P; Knops N; de Loor H; de Hoon J; Kuypers DRJ
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):50-55. PubMed ID: 29989304
[TBL] [Abstract][Full Text] [Related]
28. The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.
Flores-Pérez C; Castillejos-López MJ; Chávez-Pacheco JL; Dávila-Borja VM; Flores-Pérez J; Zárate-Castañón P; Acosta-Bastidas M; Cruz-Escobar J; Torres-Espíndola LM
J Clin Pharm Ther; 2021 Jun; 46(3):633-639. PubMed ID: 33638195
[TBL] [Abstract][Full Text] [Related]
29. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
30. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes.
Quintieri L; Palatini P; Nassi A; Ruzza P; Floreani M
Biochem Pharmacol; 2008 Mar; 75(6):1426-37. PubMed ID: 18191104
[TBL] [Abstract][Full Text] [Related]
31. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
32. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.
Eap CB; Buclin T; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
Eur J Clin Pharmacol; 2004 Jun; 60(4):231-6. PubMed ID: 15114431
[TBL] [Abstract][Full Text] [Related]
34. Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.
Guo Y; Lucksiri A; Dickinson GL; Vuppalanchi RK; Hilligoss JK; Hall SD
Clin Pharmacol Ther; 2020 Jan; 107(1):246-256. PubMed ID: 31356678
[TBL] [Abstract][Full Text] [Related]
35. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
Sanchez Spitman AB; Moes DJAR; Gelderblom H; Dezentje VO; Swen JJ; Guchelaar HJ
Eur J Clin Pharmacol; 2017 Dec; 73(12):1589-1598. PubMed ID: 28849250
[TBL] [Abstract][Full Text] [Related]
36. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
37. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
38. Variability in Expression of CYP3A5 in Human Fetal Liver.
Vyhlidal CA; Pearce RE; Gaedigk R; Calamia JC; Shuster DL; Thummel KE; Leeder JS
Drug Metab Dispos; 2015 Aug; 43(8):1286-93. PubMed ID: 25979262
[TBL] [Abstract][Full Text] [Related]
39. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
[TBL] [Abstract][Full Text] [Related]
40. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Bacchi CE; Marsh CL; McVicar JP; Barr DM; Perkins JD
J Pharmacol Exp Ther; 1994 Oct; 271(1):557-66. PubMed ID: 7965756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]